Use of pure t-butanol as a solvent for freeze-drying

A case study

Nina Ni, Marc Tesconi, S. Esmail Tabibi, Shanker Gupta, Samuel H Yalkowsky

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea, (SarCNU) (NSC-364432) is a new antitumor drug that is of interest to the National Cancer Institute. It is intended for use as an intravenous injection. Although SarCNU is sufficiently soluble in water to obtain the desired dosage, it is highly unstable. Its T90 in aqueous solution at room temperature is less than 6 h. Neat tertiary butyl alcohol (TBA), a low toxicity, high vapor pressure and low melting solvent, was determined to be an excellent freeze-drying medium. Lyophilization of SarCNU from pure TBA produces a uniform cake composed of needle-shaped crystals. Thermal analysis and gas chromatography indicate that the cake contains less than 0.001% residual solvent. The SarCNU cake can be readily reconstituted with either water or an aqueous solution of 40% propylene glycol and 10% ethanol. The reconstituted solutions are stable for 4 and 13 h, respectively.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume226
Issue number1-2
DOIs
StatePublished - Sep 11 2001

Fingerprint

tert-Butyl Alcohol
Freeze Drying
Vapor Pressure
Propylene Glycol
National Cancer Institute (U.S.)
Water
Intravenous Injections
Gas Chromatography
Antineoplastic Agents
Freezing
Needles
Ethanol
Hot Temperature
Temperature
N-methylglycinamide

Keywords

  • 1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea
  • Lyophilization
  • Tertiary butyl alcohol

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Use of pure t-butanol as a solvent for freeze-drying : A case study. / Ni, Nina; Tesconi, Marc; Tabibi, S. Esmail; Gupta, Shanker; Yalkowsky, Samuel H.

In: International Journal of Pharmaceutics, Vol. 226, No. 1-2, 11.09.2001, p. 39-46.

Research output: Contribution to journalArticle

Ni, Nina ; Tesconi, Marc ; Tabibi, S. Esmail ; Gupta, Shanker ; Yalkowsky, Samuel H. / Use of pure t-butanol as a solvent for freeze-drying : A case study. In: International Journal of Pharmaceutics. 2001 ; Vol. 226, No. 1-2. pp. 39-46.
@article{c466a1a3f8214b1c85b4620731831574,
title = "Use of pure t-butanol as a solvent for freeze-drying: A case study",
abstract = "1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea, (SarCNU) (NSC-364432) is a new antitumor drug that is of interest to the National Cancer Institute. It is intended for use as an intravenous injection. Although SarCNU is sufficiently soluble in water to obtain the desired dosage, it is highly unstable. Its T90 in aqueous solution at room temperature is less than 6 h. Neat tertiary butyl alcohol (TBA), a low toxicity, high vapor pressure and low melting solvent, was determined to be an excellent freeze-drying medium. Lyophilization of SarCNU from pure TBA produces a uniform cake composed of needle-shaped crystals. Thermal analysis and gas chromatography indicate that the cake contains less than 0.001{\%} residual solvent. The SarCNU cake can be readily reconstituted with either water or an aqueous solution of 40{\%} propylene glycol and 10{\%} ethanol. The reconstituted solutions are stable for 4 and 13 h, respectively.",
keywords = "1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea, Lyophilization, Tertiary butyl alcohol",
author = "Nina Ni and Marc Tesconi and Tabibi, {S. Esmail} and Shanker Gupta and Yalkowsky, {Samuel H}",
year = "2001",
month = "9",
day = "11",
doi = "10.1016/S0378-5173(01)00757-8",
language = "English (US)",
volume = "226",
pages = "39--46",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Use of pure t-butanol as a solvent for freeze-drying

T2 - A case study

AU - Ni, Nina

AU - Tesconi, Marc

AU - Tabibi, S. Esmail

AU - Gupta, Shanker

AU - Yalkowsky, Samuel H

PY - 2001/9/11

Y1 - 2001/9/11

N2 - 1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea, (SarCNU) (NSC-364432) is a new antitumor drug that is of interest to the National Cancer Institute. It is intended for use as an intravenous injection. Although SarCNU is sufficiently soluble in water to obtain the desired dosage, it is highly unstable. Its T90 in aqueous solution at room temperature is less than 6 h. Neat tertiary butyl alcohol (TBA), a low toxicity, high vapor pressure and low melting solvent, was determined to be an excellent freeze-drying medium. Lyophilization of SarCNU from pure TBA produces a uniform cake composed of needle-shaped crystals. Thermal analysis and gas chromatography indicate that the cake contains less than 0.001% residual solvent. The SarCNU cake can be readily reconstituted with either water or an aqueous solution of 40% propylene glycol and 10% ethanol. The reconstituted solutions are stable for 4 and 13 h, respectively.

AB - 1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea, (SarCNU) (NSC-364432) is a new antitumor drug that is of interest to the National Cancer Institute. It is intended for use as an intravenous injection. Although SarCNU is sufficiently soluble in water to obtain the desired dosage, it is highly unstable. Its T90 in aqueous solution at room temperature is less than 6 h. Neat tertiary butyl alcohol (TBA), a low toxicity, high vapor pressure and low melting solvent, was determined to be an excellent freeze-drying medium. Lyophilization of SarCNU from pure TBA produces a uniform cake composed of needle-shaped crystals. Thermal analysis and gas chromatography indicate that the cake contains less than 0.001% residual solvent. The SarCNU cake can be readily reconstituted with either water or an aqueous solution of 40% propylene glycol and 10% ethanol. The reconstituted solutions are stable for 4 and 13 h, respectively.

KW - 1-(2-Chloroethyl)-3-sarcosinamide-1-nitrosourea

KW - Lyophilization

KW - Tertiary butyl alcohol

UR - http://www.scopus.com/inward/record.url?scp=0035845724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035845724&partnerID=8YFLogxK

U2 - 10.1016/S0378-5173(01)00757-8

DO - 10.1016/S0378-5173(01)00757-8

M3 - Article

VL - 226

SP - 39

EP - 46

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -